Charles Russell Speechlys advises Kreos Capital and Silicon Valley Bank on £20 million growth capital investment in Mereo BioPharma
Charles Russell Speechlys have advised Kreos Capital and Silicon Valley Bank on a £20 million growth capital investment in Mereo BioPharma, a UK-based specialty bio-pharmaceutical company listed on the AIM market of the London Stock Exchange.
Mereo BioPharma was established to address the R&D and financial challenges faced by an increasing number of large pharmaceutical and biotech companies, and to optimise drug development and ensure that promising drug candidates fulfil their potential.
Mereo BioPharma announced to the market that it will use the financing to increase its operational and development flexibility.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Senior Associate), Amelly Kok (Associate) and Olivia Mackie (Associate) from our Corporate Team, and Daniel Sullivan (Partner) and Susan Mitchell (Senior Associate) from our Banking Team.”
News & Insights
Public Company update - November 2018
Welcome to the November edition of our biannual Public Company Update.
Governance within FCA regulated firms
We highlight the impact that the FCA’s approach to culture and governance has in our work on governance with our regulated clients
Entrepreneurs’ relief: Relief for gains arising before a dilution event
Helen Coward picks out key highlights from the draft legislation for the 18/19 Finance Bill on changes to Entrepreneurs’ Relief